Oct 5, 2020

The company seeks to address the problem of access to precision medicine for those often overlooked in emerging markets. Shares Having launched in GCC just last year, Mango Sciences’ focus on emerging markets has scored it an investment from Dubai VC, Spartech Ventures, as part of Mango’s current funding round. As a company, the UAE-based outfit seeks to address access to precision medicine for those often overlooked in emerging markets. In partnering with hospitals and clinics in the Middle East and Asia, the company uses AI to get a handle on facets such as cost of care, improving operations efficiency and enabling personalised care. “Mango’s unique ability to collaborate across the healthcare ecosystem allows us to leverage data to identify unmet needs and help finance innovative immunotherapies for patients where affordability is a key issue to access," said Dr Mohit Misra, CEO and co-founder of Mango Sciences, who is also the Head of Digital Health at the Evercare Health Fund, which focuses on Africa and Asia. Sign up for the daily Startup Digest. 0